OpenAI-Backed Biotech Firm Chai Discovery Raises $130M Series B At $1.3B Valuation
Matilda
OpenAI-Backed Biotech Firm Chai Discovery Raises $130M Series B At $1.3B Valuation
Chai Discovery Raises $130M as AI Drug Discovery Heats Up Chai Discovery, an OpenAI-backed biotech startup, has raised $130 million in a Series B funding round, pushing its valuation to $1.3 billion. The deal highlights growing investor confidence that artificial intelligence can dramatically speed up drug discovery and lower development costs. Led by General Catalyst and Oak HC/FT, the round positions Chai among a small but fast-growing group of AI-first biotech unicorns. The funding comes as pharmaceutical companies increasingly look to machine learning to tackle diseases that have resisted traditional approaches. For investors and researchers alike, the question is no longer whether AI belongs in drug development, but how quickly it can deliver real-world results. Chai’s latest raise suggests that belief is solidifying across Silicon Valley and the life sciences. It also underscores how AI models are moving from theory to practical application in medicine. Credit: Andrew Brookes / Ge…
